These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. An Efficient Automated Radiosynthesis and Bioactivity Confirmation of VMAT2 Tracer [18F]FP-(+)-DTBZ. Zhao C, Liu C, Tang J, Xu Y, Xie M, Chen Z. Mol Imaging Biol; 2020 Apr; 22(2):265-273. PubMed ID: 31165386 [Abstract] [Full Text] [Related]
3. Deuterated 18F-9-O-hexadeutero-3-fluoropropoxyl-(+)-dihydrotetrabenazine (D6-FP-(+)-DTBZ): A vesicular monoamine transporter 2 (VMAT2) imaging agent. Liu F, Choi SR, Zha Z, Ploessl K, Zhu L, Kung HF. Nucl Med Biol; 2018 Feb; 57():42-49. PubMed ID: 29306111 [Abstract] [Full Text] [Related]
4. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Goswami R, Ponde DE, Kung MP, Hou C, Kilbourn MR, Kung HF. Nucl Med Biol; 2006 Aug; 33(6):685-94. PubMed ID: 16934687 [Abstract] [Full Text] [Related]
5. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters. Kung MP, Hou C, Goswami R, Ponde DE, Kilbourn MR, Kung HF. Nucl Med Biol; 2007 Apr; 34(3):239-46. PubMed ID: 17383573 [Abstract] [Full Text] [Related]
6. MicroPET imaging of vesicular monoamine transporter 2 revealed the potentiation of (+)-dihydrotetrabenazine on MPTP-induced degeneration of dopaminergic neurons. Xu Y, Tang J, Liu C, Zhao C, Cao S, Yu H, Chen Z, Xie M. Nucl Med Biol; 2021 Apr; 96-97():9-18. PubMed ID: 33647803 [Abstract] [Full Text] [Related]
7. PET Imaging of Vesicular Monoamine Transporter 2 in Early Diabetic Retinopathy Using [18F]FP-(+)-DTBZ. Li J, Chen P, Bao Y, Sun Y, He J, Liu X. Mol Imaging Biol; 2020 Oct; 22(5):1161-1169. PubMed ID: 31650482 [Abstract] [Full Text] [Related]
11. Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET. Lin KJ, Weng YH, Hsieh CJ, Lin WY, Wey SP, Kung MP, Yen TC, Lu CS, Hsiao IT. PLoS One; 2013 Oct; 8(9):e75952. PubMed ID: 24098749 [Abstract] [Full Text] [Related]
16. PET imaging with [18F]FP-(+)-DTBZ in 6-OHDA-induced partial and full unilaterally-lesioned model rats of Parkinson's disease and the correlations to the biological data. Tang J, Xu Y, Liu C, Fang Y, Cao S, Zhao C, Huang H, Zou M, Chen Z. Nucl Med Biol; 2020 Oct; 90-91():1-9. PubMed ID: 32861175 [Abstract] [Full Text] [Related]
17. Effects of anesthetics on vesicular monoamine transporter type 2 binding to ¹⁸F-FP-(+)-DTBZ: a biodistribution study in rat brain. Chen Z, Tang J, Liu C, Li X, Huang H, Xu X, Yu H. Nucl Med Biol; 2016 Jan; 43(1):124-129. PubMed ID: 26526872 [Abstract] [Full Text] [Related]
18. Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging. Weng CC, Chen ZA, Chao KT, Ee TW, Lin KJ, Chan MH, Hsiao IT, Yen TC, Kung MP, Hsu CH, Wey SP. PLoS One; 2017 Jan; 12(3):e0173503. PubMed ID: 28257461 [Abstract] [Full Text] [Related]
19. [18F]FP-(+)-DTBZ PET study in a lactacystin-treated rat model of Parkinson disease. Weng CC, Huang SL, Chen ZA, Lin KJ, Hsiao IT, Yen TC, Kung MP, Wey SP, Hsu CH. Ann Nucl Med; 2017 Aug; 31(7):506-513. PubMed ID: 28451991 [Abstract] [Full Text] [Related]
20. Synthesis and biological evaluation of 3-alkyl-dihydrotetrabenazine derivatives as vesicular monoamine transporter-2 (VMAT2) ligands. Zheng P, Lieberman BP, Choi SR, Plöessl K, Kung HF. Bioorg Med Chem Lett; 2011 Jun 01; 21(11):3435-8. PubMed ID: 21531556 [Abstract] [Full Text] [Related] Page: [Next] [New Search]